4 years ago

Glyconics Raises £1.5 Million for Diabetes Screening Device

  • Glyconics, a UK-based medtech startup, has raised £1.5 million in an oversubscribed Enterprise Investment Scheme (EIS) funding round

  • The raise was led by investment platform Wealth Club and existing investors, Deepbridge Capital and Boundary Capital

  • The funds will be used to conduct a large-scale trial programme of Glyconics' point-of-care diabetes screening tool, Glyconics-SX, before applying for regulatory approval and CE marking

  • Glyconics' non-invasive handheld device uses miniaturised infra-red (IR) spectrometry to detect biomarker changes in a patient's fingernail within seconds, offering a cost-efficient and rapid alternative to traditional blood or urine tests.

      • ProblemHealthcare

      "Diabetes is a global epidemic with severe complications, and early detection is crucial. However, current screening methods rely on invasive blood or urine tests that are costly, resource-intensive, and prone to inaccuracies."

      Solution

      "Glyconics offers a non-invasive, cost-efficient, and rapid diabetes screening tool using infrared light. This handheld device analyzes fingernails for biomarker changes, providing results in seconds without the need for single-use plastics."

      Covered on